Fennec Pharmaceuticals Inc
NASDAQ:FENC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bank Of India Indonesia Tbk PT
IDX:BSWD
|
ID |
|
L
|
Lotus KFM Bhd
KLSE:LOTUS
|
MY |
Fennec Pharmaceuticals Inc
Research & Development
Fennec Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fennec Pharmaceuticals Inc
NASDAQ:FENC
|
Research & Development
-$250k
|
CAGR 3-Years
59%
|
CAGR 5-Years
45%
|
CAGR 10-Years
0%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Research & Development
-$523m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-31%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Fennec Pharmaceuticals Inc
Glance View
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 10 full-time employees. The company went IPO on 2001-06-05. The firm is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical-stage of development is PEDMARK. The company announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). PEDMARK has the potential to reduce the incidence and/or grade of chemotherapy-induced hearing loss. The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.
See Also
What is Fennec Pharmaceuticals Inc's Research & Development?
Research & Development
-250k
USD
Based on the financial report for Dec 31, 2025, Fennec Pharmaceuticals Inc's Research & Development amounts to -250k USD.
What is Fennec Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
0%
Over the last year, the Research & Development growth was 19%. The average annual Research & Development growth rates for Fennec Pharmaceuticals Inc have been 59% over the past three years , 45% over the past five years .
